Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCAPE: Amuvatinib + Platinum-Etoposide in SCLC
NCT01357395Phase 2Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- May 2011
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of amuvatinib in small cell lung cancer (SCLC), sponsored by Astex Pharmaceuticals. Primary endpoint: Overall Objective Response Rate at 3 months. Started May 2011; status: completed.
02
Drugs
amuvatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01357395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01357395.